Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 10867029 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Gijón MA, et al. (2000) Cytosolic phospholipase A2 is required for macrophage arachidonic acid release by agonists that Do and Do not mobilize calcium. Novel role of mitogen-activated protein kinase pathways in cytosolic phospholipase A2 regulation. J Biol Chem 275, 20146-56 10867029
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S505-p - cPLA2 (mouse)
Orthologous residues
cPLA2 (human): S505‑p, cPLA2 (mouse): S505‑p, cPLA2 (rat): S505‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
SB202190 zymosan no effect upon treatment-induced increase
U0126 zymosan no effect upon treatment-induced increase
SB202190, U0126 zymosan inhibit treatment-induced increase
okadaic acid no change compared to control
SB202190 okadaic acid no change compared to control
U0126 okadaic acid no change compared to control
anisomycin no change compared to control
SB202190 anisomycin no change compared to control

T203-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
A23187 no change compared to control
phorbol ester increase
zymosan increase
U0126 zymosan inhibit treatment-induced increase
SB202190 zymosan no effect upon treatment-induced increase
SB202190, U0126 SB202190, zymosan inhibit treatment-induced increase
okadaic acid increase
anisomycin no change compared to control
Downstream Regulation
 Effect of modification (process):  transcription, altered

Y205-p - ERK1 (mouse)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
A23187 no change compared to control
phorbol ester increase
zymosan increase
U0126 zymosan inhibit treatment-induced increase
SB202190 zymosan no effect upon treatment-induced increase
SB202190, U0126 SB202190, zymosan inhibit treatment-induced increase
okadaic acid increase
anisomycin no change compared to control
Downstream Regulation
 Effect of modification (process):  transcription, altered

T183-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
A23187 no change compared to control
phorbol ester increase
zymosan increase
U0126 zymosan inhibit treatment-induced increase
SB202190 zymosan no effect upon treatment-induced increase
SB202190, U0126 SB202190, zymosan inhibit treatment-induced increase
okadaic acid increase
anisomycin no change compared to control
Downstream Regulation
 Effect of modification (process):  transcription, altered

Y185-p - ERK2 (mouse)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
A23187 no change compared to control
phorbol ester increase
zymosan increase
U0126 zymosan inhibit treatment-induced increase
SB202190 zymosan no effect upon treatment-induced increase
SB202190, U0126 SB202190, zymosan inhibit treatment-induced increase
okadaic acid increase
anisomycin no change compared to control
Downstream Regulation
 Effect of modification (process):  transcription, altered

T183-p - JNK1 (mouse)
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
okadaic acid increase
anisomycin increase
phorbol ester no change compared to control

Y185-p - JNK1 (mouse)
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
okadaic acid increase
anisomycin increase
phorbol ester no change compared to control

T183-p - JNK2 (mouse)
Orthologous residues
JNK2 (human): T183‑p, JNK2 iso2 (human): T183‑p, JNK2 iso3 (human): T183‑p, JNK2 (mouse): T183‑p, JNK2 (rat): T183‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
okadaic acid increase
anisomycin increase
phorbol ester no change compared to control

Y185-p - JNK2 (mouse)
Orthologous residues
JNK2 (human): Y185‑p, JNK2 iso2 (human): Y185‑p, JNK2 iso3 (human): Y185‑p, JNK2 (mouse): Y185‑p, JNK2 (rat): Y185‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
okadaic acid increase
anisomycin increase
phorbol ester no change compared to control

T180-p - P38A (mouse)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
okadaic acid increase
anisomycin increase
phorbol ester increase
Downstream Regulation
 Effect of modification (process):  transcription, altered

Y182-p - P38A (mouse)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  macrophage-peritoneum
 Cellular systems studied:  primary cultured cells
 Species studied:  mouse
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
zymosan increase
okadaic acid increase
anisomycin increase
phorbol ester increase
Downstream Regulation
 Effect of modification (process):  transcription, altered


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.